Floatz logo

Dual-Target Car-Nk Cell Product

Recurrent or Refractory Disease After Standard Therapies

Beijing BiotechCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Recurrent or Refractory Disease After Standard Therapies cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 1/2CCC
Fludarabine
Beijing Biotech
Phase 1/2CCC

Same molecule, other indications

Dual-Target Car-Nk Cell Product is also rated in:

Fallopian Tube CarcinomaDormant
CC
Indicative ·
47 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
45 / 100
View asset →
ovarian carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →